{"id":"naloxone-ketamine","safety":{"commonSideEffects":[{"rate":null,"effect":"Dissociation"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Emergence reactions"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a combination product pairing an opioid antagonist (naloxone) with a dissociative anesthetic (ketamine). Naloxone competitively blocks mu, delta, and kappa opioid receptors, rapidly reversing opioid-induced respiratory depression and overdose. Ketamine antagonizes NMDA glutamate receptors, producing anesthesia, analgesia, and dissociation. The combination may be used in emergency settings where both opioid reversal and anesthetic/analgesic effects are therapeutically desired.","oneSentence":"Naloxone blocks opioid receptors to reverse opioid overdose, while ketamine provides dissociative anesthesia and analgesia through NMDA receptor antagonism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:56:36.777Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid overdose reversal with concurrent anesthesia/analgesia requirement (investigational/research use)"}]},"trialDetails":[{"nctId":"NCT07435077","phase":"PHASE4","title":"Examining Analgesic Synergy and Efficacy in Trauma Care","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":282},{"nctId":"NCT04600089","phase":"PHASE2","title":"Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI","status":"RECRUITING","sponsor":"Sam Tyagi","startDate":"2020-12-08","conditions":"Descending Aortic Dissection, Postoperative Pain, Thoracoabdominal Aortic Aneurysm","enrollment":30},{"nctId":"NCT02461927","phase":"PHASE1, PHASE2","title":"Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2015-01-01","conditions":"Major Depressive Disorder, Alcohol Use Disorder","enrollment":65},{"nctId":"NCT05940324","phase":"PHASE2","title":"Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-02-24","conditions":"Obsessive-Compulsive Disorder","enrollment":150},{"nctId":"NCT04562779","phase":"EARLY_PHASE1","title":"Inpatient Single Dose Interventions for Alcohol Use Disorder","status":"COMPLETED","sponsor":"Denver Health and Hospital Authority","startDate":"2021-01-19","conditions":"Alcohol Use Disorder, Severe","enrollment":44},{"nctId":"NCT04977674","phase":"EARLY_PHASE1","title":"Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine","status":"COMPLETED","sponsor":"King's College London","startDate":"2021-09-27","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":27},{"nctId":"NCT05360030","phase":"NA","title":"Mechanism of Analgesic Effect on Prolonged Continuous Theta Burst Stimulation","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-14","conditions":"Chronic Pain, rTMS","enrollment":45},{"nctId":"NCT04365985","phase":"PHASE2","title":"Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19","status":"TERMINATED","sponsor":"Corewell Health East","startDate":"2020-04-29","conditions":"COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS)","enrollment":70},{"nctId":"NCT03658330","phase":"PHASE2","title":"Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder","status":"COMPLETED","sponsor":"VA Connecticut Healthcare System","startDate":"2016-05","conditions":"Major Depressive Disorder, Alcohol Use Disorder","enrollment":5},{"nctId":"NCT02911597","phase":"PHASE1","title":"Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2016-09","conditions":"Depression","enrollment":16},{"nctId":"NCT00921765","phase":"PHASE4","title":"Reversal of Ketamine Pharmacodynamic Effects With Naloxone","status":"TERMINATED","sponsor":"Ullevaal University Hospital","startDate":"2009-12","conditions":"Pain","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":302,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Naloxone","ATC code: V03A B15","Ketamine","ATC code: N01A X03"],"phase":"marketed","status":"active","brandName":"Naloxone + Ketamine","genericName":"Naloxone + Ketamine","companyName":"Ullevaal University Hospital","companyId":"ullevaal-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naloxone blocks opioid receptors to reverse opioid overdose, while ketamine provides dissociative anesthesia and analgesia through NMDA receptor antagonism. Used for Opioid overdose reversal with concurrent anesthesia/analgesia requirement.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":7,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}